Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age5-60
SponsorSouth Valley University
About this trial
Mycobacterium leprae is a slow-growing bacillus that causes leprosy. the infection may take two to ten years to incubate. While the exact mechanism of infection transmission is unknown, direct bacillus absorption through the nasal or respiratory mucosa and aerosolized nasal secretions are the most common theories. The bacteria is subsequently transported by the bloodstream to the peripheral nerves, where it can result in tissue damage from painless burns and ulcers as well as irreparable nerve damage that results in a loss of protective feeling.
Eligibility criteria
Qualifiers
Patients of both sexes with positive slit skin smear for m.leprae .
Disqualifiers
Patients with hypersensitivity to sulfa .
Patients with hypersensitivity to clofazimine or rifampcin.
pregnant or lactating women.
Trial design
Treatments tested in this trial
- Dapsone
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov